Dr Victoria Grandage

Dr Victoria GrandageTel: 0203 447 5239
Fax: 020 3447 5827

University College Hospital

Blood Diseases (clinical haematology), Long-term-follow-up (LTFU): Late effects of Cancer, Children and young people's services

Professional background

MBChB, University of Dundee 1991. My initial training was in general adult medicine gaining membership of the Royal College of Physicians in 1995. I spent 21/2 years as Clinical Fellow in Bone marrow transplantation at the Royal Hospital for Sick Children in Bristol where I also undertook a period of research in minimal residual disease in acute lymphoblastic leukaemia. My General Haematology training (MRCPath 2005, FRCPath 2008) was predominantly gained at University College Hospital London and Great Ormond Street Hospital and included a further period of training in bone marrow transplantation. During this time I undertook a period of research (2001-2004) gaining a phD in signal transduction in acute myeloid leukaemia (2001). My training in paediatric and adult haematology led me to develop an interest in adolescent haematology and I was appointed as Consultant Haematologist for the Children and Young People’s Cancer Service at UCLH in April 2007.

Research interests

  • Acute myeloid leukaemia
  • Non-malignant haematology
  • Bone marrow transplantation
  • Late effects of cancer treatment


Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation.
V L Grandage M N Potter, D H Pamphilon, C G Steward, J M Cornish, A Oakhill, D I Marks.
Bone Marrow Transplantation, April 98, Vol 21, (7) 687-690.

Minimal residual disease status, as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia.
C J C Knechtli, N J Goulden, J P Hancock, V L Grandage, E L Harris, R J Garland, C G Jones, A F Green, E Clark, A W Lankester, M N Potter, D I Marks, J M Cornish, D H Pamphilon, C G Steward and A Oakhill. 
British Journal of Haematology August 98, Vol 102, (3) 860.

Minimal residual disease status prior to allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.
C J C Knechtli, N.J Goulden, J P Hancock V L Grandage, E L Harris, R J Garland, C G Jones,A F Green, E Clarke, A W Lankester, M N Potter, D I Marks, J M Cornish, D H Pamphilon, C G Steward and A Oakhill
Blood 1998 Dec 1;92 (11):4072-9

Lack of effect of the human GM-CSF analogue E21R on the survival of primary human acute myeloid leukemia cells
Jakupovic I, Grandage VL, Linch DC, Khwaja A.
Blood  2004 Apr 15;103(8):3230-2.

PI3-Kinase/Akt Is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPKinase and p53 pathways.
Victoria. L. Grandage, Rosemary. E. Gale. David. C. Linch, Asim Khwaja
Leukemia. 2005 Apr;19(4):586-94.

Constitutive activation of the Wnt/-catenin signalling pathway in acute
myeloid leukaemia
Maria Simon, Victoria L Grandage,  David C Linch and Asim Khwaja.
Oncogene. 2005 Mar 31;24(14):2410-20.

A selective inhibitor of the p110 delta isoform of PI3-Kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.
Billotet C, Grandage V, Gale RE, Quattropani A, Rommel C, Vanhaesebroek B, Khwaja A.Oncogene 2006 May 15

Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
Grandage VL, Everington T, Linch DC, Khwaja A.
Br J Haematol 2006 Sept 4

GMC/GDC number: 3542974 

 Web chat